On Heels Of Rejection, Mylan Gets Letter From Teva

On the heels of being rejected in its attempt to merge with a rival, Mylan N.V. got a letter Wednesday afternoon from its own would-be suitor, Teva Pharmaceuticals International Inc. , laying out the case for a Teva-Mylan combination.